Information Provided By: 
Fly News Breaks for September 3, 2019
BSX
Sep 3, 2019 | 06:16 EDT
Barclays analyst Kristen Stewart reinstated coverage of Boston Scientific with an Overweight rating and $48 price target. With multiple new products across all of its business units, the company is well positioned to sustain high-single digit organic sales growth for the foreseeable future, Stewart tells investors in a research note. She believes the consensus view on the stock "is the right view."
News For BSX From the Last 2 Days
